Antifungal prophylaxis against invasive Candida and Aspergillus infection in adult heart transplant recipients: protocol for a systematic review and meta-analysis.

IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY European journal of hospital pharmacy : science and practice Pub Date : 2024-07-02 DOI:10.1136/ejhpharm-2024-004266
Zahra Irshad, Abi Jenkins, Hoong Sern Lim, Ian D Maidment
{"title":"Antifungal prophylaxis against invasive <i>Candida</i> and <i>Aspergillus</i> infection in adult heart transplant recipients: protocol for a systematic review and meta-analysis.","authors":"Zahra Irshad, Abi Jenkins, Hoong Sern Lim, Ian D Maidment","doi":"10.1136/ejhpharm-2024-004266","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Invasive fungal infections (IFI) can contribute to increased mortality and morbidity rates after heart transplant in adults. The most common causes are <i>Aspergillus</i> and <i>Candida</i> species. There is uncertainty on how effective antifungal prophylaxis is against <i>Candida</i> spp infections and limited guidance on the prevention of <i>Aspergillus</i> spp infections. This systematic review and meta-analysis will assess the literature to see if antifungal prophylaxis reduces the incidence of IFI after heart transplant in adults.</p><p><strong>Methods and analysis: </strong>This systematic review protocol follows the Preferred Reporting Items for Systematic reviews and Meta Analysis guidelines. A systematic search of the Cochrane Library, Web of Science, Scopus, Embase, MEDLINE, and Proquest databases will be undertaken. Reference lists of retrieved publications and conference abstracts will also be searched. Title, abstract and full-text screening will be undertaken by two reviewers. Discrepancies will be resolved by a third reviewer. Studies with paediatric patients, multi-organ transplants, or patients with a second heart transplant will be excluded, along with those who do not have clear definitions and diagnostic criteria for IFI. Risk of bias will be assessed using the Cochrane Risk of Bias 2 tool and the Risk of Bias in Non-randomised Studies of Interventions tool. A meta-analysis will be carried out, but if studies are not deemed to be sufficiently similar, only a narrative synthesis will be undertaken.</p><p><strong>Ethics and dissemination: </strong>Ethical approval is not required for this systematic review as primary data will not be collected. The results of the review will be disseminated through publication in an academic journal and scientific conferences.</p><p><strong>Prospero registration number: </strong>CRD42024516588.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of hospital pharmacy : science and practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2024-004266","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Invasive fungal infections (IFI) can contribute to increased mortality and morbidity rates after heart transplant in adults. The most common causes are Aspergillus and Candida species. There is uncertainty on how effective antifungal prophylaxis is against Candida spp infections and limited guidance on the prevention of Aspergillus spp infections. This systematic review and meta-analysis will assess the literature to see if antifungal prophylaxis reduces the incidence of IFI after heart transplant in adults.

Methods and analysis: This systematic review protocol follows the Preferred Reporting Items for Systematic reviews and Meta Analysis guidelines. A systematic search of the Cochrane Library, Web of Science, Scopus, Embase, MEDLINE, and Proquest databases will be undertaken. Reference lists of retrieved publications and conference abstracts will also be searched. Title, abstract and full-text screening will be undertaken by two reviewers. Discrepancies will be resolved by a third reviewer. Studies with paediatric patients, multi-organ transplants, or patients with a second heart transplant will be excluded, along with those who do not have clear definitions and diagnostic criteria for IFI. Risk of bias will be assessed using the Cochrane Risk of Bias 2 tool and the Risk of Bias in Non-randomised Studies of Interventions tool. A meta-analysis will be carried out, but if studies are not deemed to be sufficiently similar, only a narrative synthesis will be undertaken.

Ethics and dissemination: Ethical approval is not required for this systematic review as primary data will not be collected. The results of the review will be disseminated through publication in an academic journal and scientific conferences.

Prospero registration number: CRD42024516588.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
成人心脏移植受者预防侵袭性念珠菌和曲霉菌感染的抗真菌疗法:系统综述和荟萃分析方案。
导言:侵袭性真菌感染(IFI)可导致成人心脏移植后的死亡率和发病率上升。最常见的病因是曲霉菌和念珠菌。目前尚不确定抗真菌预防措施对念珠菌感染有多大效果,对曲霉菌感染的预防指导也很有限。本系统综述和荟萃分析将对文献进行评估,以了解抗真菌预防是否能降低成人心脏移植后 IFI 的发病率:本系统综述方案遵循《系统综述和荟萃分析首选报告项目》(Preferred Reporting Items for Systematic reviews and Meta Analysis)指南。将对 Cochrane Library、Web of Science、Scopus、Embase、MEDLINE 和 Proquest 数据库进行系统检索。还将检索检索到的出版物的参考文献列表和会议摘要。标题、摘要和全文将由两名审稿人进行筛选。不一致之处将由第三位审稿人解决。儿科患者、多器官移植患者或二次心脏移植患者的研究将被排除在外,那些对 IFI 没有明确定义和诊断标准的研究也将被排除在外。偏倚风险将使用 Cochrane Risk of Bias 2 工具和非随机干预研究偏倚风险工具进行评估。将进行荟萃分析,但如果认为研究不够相似,则只进行叙述性综合分析:由于不收集原始数据,本系统综述不需要伦理批准。审查结果将通过在学术期刊和科学会议上发表来传播:CRD42024516588。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.40
自引率
5.90%
发文量
104
审稿时长
6-12 weeks
期刊介绍: European Journal of Hospital Pharmacy (EJHP) offers a high quality, peer-reviewed platform for the publication of practical and innovative research which aims to strengthen the profile and professional status of hospital pharmacists. EJHP is committed to being the leading journal on all aspects of hospital pharmacy, thereby advancing the science, practice and profession of hospital pharmacy. The journal aims to become a major source for education and inspiration to improve practice and the standard of patient care in hospitals and related institutions worldwide. EJHP is the only official journal of the European Association of Hospital Pharmacists.
期刊最新文献
Mobile pharmacies of the Ukrainian chain 'Apteka 9-1-1': access to medicines during the war in Ukraine. Integrating automated dispensing cabinets into the medication dispensing process: feedback from the practice in European hospitals. Cardiovascular events in eGFR-mutation non-small-cell lung cancer patients on osimertinib. Ceftaroline combination therapy for methicillin resistant coagulase negative Staphylococcus bacteraemia and endocarditis. Predictive performance of glomerular filtration rate equations based on cystatin C, creatinine and their combination in critically ill patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1